Komori
Fuso Pharmaceutical Industries (4538) · FactUpdated: full-year revenue growth, lower operating and ordinary profit, and net income recoveryLatest Earnings (2026-08-10): "Other"

Revenue Decline and Sharp Profit Drop

First written in FY2016. . Latest entry: 2026-08-10.

38entries
11years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2016 – 2026-08-102016: 320162017: 420172018: 420182019: 420192020: 420202021: 420212022: 420222023: 420232024: 320242025: 220252026: 22026
Same theme, other companies
Performance trends diverging between revenue and order growth and changes in profitA theme 255 companies write about · 50 as a headwind · 74 as a tailwind

The whole theme swung hardest in 2020: 29 of 143 companies on the "Worse" side.

86 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 168 companies compared. The sentences above are computed from all 168.Comparing 200 of the theme's 293 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-08-10OtherEarnings

    「As a result, revenue for the first quarter increased by ¥543 million, or 3.5%, year on year to ¥16,046 million, due in part to the effectiveness of sales-promotion activities despite the negative impact of the drug-price revision on generic-drug sales. In terms of earnings, operating income increased by ¥375 million, or 63.0%, to ¥972 million, ordinary income increased by ¥264 million, or 40.9%, to ¥911 million, and quarterly net income increased by ¥180 million, or 39.0%, to ¥642 million, all compared with the same quarter of the previous year.」

    Revenue increased in the first quarter, while operating income, ordinary income and quarterly net income also rose year on year.
  2. FY2026Updated: full-year revenue growth, lower operating and ordinary profit, and net income recoveryAnnual report

    「As a result, for the fiscal year, revenue increased to ¥62,307 million, up ¥1,744 million, or 2.9%, from the previous fiscal year, mainly due to promotion of generic drugs related to renal and dialysis care. On the profit front, although raw material costs and various logistics-related expenses continued to rise, unprofitability across infusion products was mitigated by the effects of increased production and exceptional repricing of unprofitable products, resulting in a slight improvement in the cost-of-sales ratio. Operating profit increased ¥2,167 million, or 110.3%, to ¥4,131 million, while ordinary profit increased ¥1,912 million, or 102.4%, to ¥3,780 million. In addition, on 13 December 2018, TORAY INDUSTRIES,INC. filed a lawsuit with the Tokyo District Court seeking an injunction against patent infringement and other relief concerning Nalfurafine Hydrochloride OD Tablets 2.5 μg “Fuso,” an oral antipruritic agent [representative originator product: Remitch OD Tablets 2.5 μg]. The Tokyo District Court subsequently ruled to dismiss TORAY INDUSTRIES,INC.’s claims, and on 30 March 2021, TORAY INDUSTRIES,INC., dissatisfied with the ruling, appealed to the Intellectual Property High Court. On 27 May 2025, the Intellectual Property High Court partially upheld TORAY INDUSTRIES,INC.’s claims and ordered the company to pay a total of ¥7,472,878,838 plus damages for delay. In connection with the judgment, the company recorded ¥8,744 million as a provision for litigation-related losses under extraordinary losses, resulting in a net loss of ¥3,288 million for the fiscal year, compared with net profit of ¥1,377 million in the previous fiscal year.」

    Full-year revenue increased 2.9% year on year, while operating profit declined 36.1% and ordinary profit declined 37.9%. Net profit was ¥2,011 million, reflecting the reversal of the previous year’s patent litigation-related losses.
  3. FY2026-H1Updated interim revenue growth, operating profit decline, ordinary profit decline, and net profit declineAnnual report

    「As a result, during the interim period, revenue increased to ¥31,229 million, up ¥1,490 million, or 5.0%, from the previous interim period, mainly due to promotion of generic drugs related to renal and dialysis care. On the profit front, operating profit decreased ¥1,186 million, or 48.8%, to ¥1,247 million, and ordinary profit decreased ¥1,012 million, or 47.2%, to ¥1,131 million, due to a greater-than-expected rise in the cost-of-sales ratio resulting from higher raw material and labor costs, as well as an increase in research and development expenses accompanying progress in R&D activities related to DMX-200. Interim net profit also decreased ¥703 million, or 45.8%, to ¥831 million.」

    In the interim period, revenue increased 5.0% year on year, while operating profit declined 48.8%, ordinary profit declined 47.2%, and interim net profit declined 45.8% due to a higher cost-of-sales ratio resulting from increases in raw material and labor costs, as well as higher R&D expenses for DMX-200 and other factors.
  4. FY2025Updated full-year revenue growth, operating profit growth, ordinary profit growth, and net loss due to litigation lossesAnnual report

    「As a result, for the fiscal year, revenue increased to ¥60,563 million, up ¥5,155 million, or 9.3%, from the previous fiscal year, mainly due to increased manufacturing and sales resulting from the promotion of generic drugs related to renal and dialysis care and substitute supply of other companies’ infusion and injectable products. On the profit front, although raw material costs and various logistics-related expenses continued to rise, unprofitability across infusion products was mitigated by the effects of increased production and exceptional repricing of unprofitable products, resulting in a slight improvement in the cost-of-sales ratio. Operating profit increased ¥2,167 million, or 110.3%, to ¥4,131 million, while ordinary profit increased ¥1,912 million, or 102.4%, to ¥3,780 million. In addition, on 13 December 2018, TORAY INDUSTRIES,INC. filed a lawsuit with the Tokyo District Court seeking an injunction against patent infringement and other relief concerning Nalfurafine Hydrochloride OD Tablets 2.5 μg “Fuso,” an oral antipruritic agent [representative originator product: Remitch OD Tablets 2.5 μg]. The Tokyo District Court subsequently ruled to dismiss TORAY INDUSTRIES,INC.’s claims, and on 30 March 2021, TORAY INDUSTRIES,INC., dissatisfied with the ruling, appealed to the Intellectual Property High Court. On 27 May 2025, the Intellectual Property High Court partially upheld TORAY INDUSTRIES,INC.’s claims and ordered the company to pay a total of ¥7,472,878,838 plus damages for delay. In connection with the judgment, the company recorded ¥8,744 million as a provision for litigation-related losses under extraordinary losses, resulting in a net loss of ¥3,288 million for the fiscal year, compared with net profit of ¥1,377 million in the previous fiscal year.」

    Full-year revenue increased 9.3% year on year, operating profit rose 110.3%, and ordinary profit rose 102.4%, while a net loss of ¥3,288 million was recorded due to extraordinary losses related to the patent litigation.
  5. FY2025-H1Record interim revenue growth and substantial profit growthAnnual report

    「As a result, revenue for the interim accounting period increased ¥2,314 million, or 8.4%, year on year to ¥29,739 million, due to the effects of increased production and sales resulting from promotional efforts for generic drugs related to renal care and dialysis and the replacement supply of other companies' infusion and injectable products, among other factors. Although raw material, logistics and other related costs continued to rise, increased production and the effects of exceptional repricing of unprofitable products eased the overall unprofitability of infusion products and slightly improved the cost of sales ratio. Operating profit increased ¥1,335 million, or 121.4%, to ¥2,434 million, ordinary profit increased ¥1,045 million, or 95.2%, to ¥2,143 million, and interim net income increased ¥818 million, or 114.2%, to ¥1,535 million.」

    In the interim period, revenue increased 8.4% year on year, operating profit rose 121.4%, ordinary profit rose 95.2%, and interim net profit rose 114.2%. The company cited promotion of generic drug sales and substitute supply of other companies’ products as factors behind the revenue increase, and mitigation of unprofitable infusion products and a slight improvement in the cost-of-sales ratio as factors behind the profit increase.
  6. FY2024Record full-year revenue growth and profit declineAnnual report

    「As a result, full-year revenue increased ¥4,391 million, or 8.6%, year on year to ¥55,407 million due to higher generic drug sales and other factors. The higher cost of sales ratio caused by surging raw material prices reduced operating profit by ¥242 million, or 11.0%, to ¥1,964 million, ordinary profit by ¥347 million, or 15.7%, to ¥1,868 million, and net income by ¥228 million, or 14.2%, to ¥1,377 million.」

    Revenue increased 8.6%, while operating profit, ordinary profit and net income declined due to the higher cost of sales ratio resulting from surging raw material prices and other factors.
  7. FY2024-Q3Record cumulative nine-month revenue growth and profit declineAnnual report

    「As a result, revenue for the cumulative nine months increased ¥3,610 million, or 9.2%, year on year to ¥42,830 million due to higher generic drug sales and other factors. The higher cost of sales ratio caused by surging raw material prices reduced operating profit by ¥122 million, or 6.3%, to ¥1,843 million, ordinary profit by ¥231 million, or 11.2%, to ¥1,829 million, and quarterly net income by ¥266 million, or 17.8%, to ¥1,227 million.」

    Revenue increased 9.2% due to higher generic drug sales and other factors, while operating profit, ordinary profit and quarterly net income all declined due to the higher cost of sales ratio resulting from surging raw material prices.
  8. FY2024-Q2Record first-half revenue growth and profit declineAnnual report

    「As a result, revenue for the cumulative first half increased ¥2,053 million, or 8.1%, year on year to ¥27,424 million due to higher generic drug sales and other factors. The higher cost of sales ratio caused by surging raw material prices reduced operating profit by ¥185 million, or 14.4%, to ¥1,099 million, ordinary profit by ¥301 million, or 21.5%, to ¥1,098 million, and quarterly net income by ¥301 million, or 29.6%, to ¥717 million.」

    In the cumulative first half, revenue increased 8.1%, while operating profit declined 14.4%, ordinary profit declined 21.5% and quarterly net income declined 29.6%.
  9. FY2024-Q1Record first-quarter revenue growth and profit declineAnnual report

    「As a result, revenue for the cumulative first quarter increased ¥1,140 million, or 9.2%, year on year to ¥13,507 million due to higher generic drug sales and other factors. However, increases in the cost of sales ratio due to higher raw material prices and other factors caused operating profit to decrease ¥32 million, or 5.2%, to ¥589 million, ordinary profit to decrease ¥116 million, or 15.0%, to ¥658 million, and quarterly net income to decrease ¥79 million, or 14.2%, to ¥479 million.」

    Revenue increased due to higher generic drug sales and other factors, while operating profit, ordinary profit and quarterly net income declined due to the higher cost of sales ratio resulting from rising raw material prices and other factors.
  10. FY2023Record full-year revenue and profit growthAnnual report

    「As a result, revenue for the fiscal year increased ¥1,382 million, or 2.8%, year on year to ¥51,015 million due to higher generic drug sales and other factors. Higher revenue resulted in operating profit increasing ¥282 million, or 14.7%, to ¥2,206 million and ordinary profit increasing ¥218 million, or 11.0%, to ¥2,215 million. Net income increased ¥122 million, or 8.3%, to ¥1,605 million.」

    FY2023 full-year revenue, operating profit, ordinary profit and net income all increased year on year.
  11. FY2023-Q3Record cumulative nine-month revenue growth, operating and ordinary profit growth, and slight net income declineAnnual report

    「As a result, revenue for the cumulative nine months increased ¥948 million, or 2.5%, year on year to ¥39,219 million due to higher generic drug sales and other factors. Operating profit increased ¥35 million, or 1.8%, to ¥1,965 million and ordinary profit increased ¥53 million, or 2.7%, to ¥2,060 million, while quarterly net income decreased ¥1 million, or 0.1%, to ¥1,493 million.」

    In the cumulative nine months, revenue, operating profit and ordinary profit increased year on year, while quarterly net income decreased 0.1%.
  12. FY2023-Q2Record cumulative second-quarter revenue growth, operating and ordinary profit growth, and net income declineAnnual report

    「As a result, revenue for the cumulative first half increased ¥404 million, or 1.6%, year on year to ¥25,371 million due to higher generic drug sales and other factors. Operating profit increased ¥31 million, or 2.5%, to ¥1,285 million and ordinary profit increased ¥46 million, or 3.4%, to ¥1,399 million, while quarterly net income decreased ¥25 million, or 2.4%, to ¥1,018 million.」

    In the cumulative first half, revenue, operating profit and ordinary profit increased, while quarterly net income decreased 2.4% year on year.
  13. FY2023-Q1Record first-quarter revenue decline, operating profit growth, ordinary profit decline and net income growthAnnual report

    「As a result, revenue for the cumulative first quarter decreased ¥232 million, or 1.8%, year on year to ¥12,367 million due to the impact of drug price revisions and other factors. Improvements in the cost of sales ratio resulted in operating profit increasing ¥9 million, or 1.6%, to ¥622 million and quarterly net income increasing ¥11 million, or 2.1%, to ¥559 million, while ordinary profit decreased ¥5 million, or 0.8%, to ¥774 million.」

    The impact of drug price revisions and other factors caused revenue to decline 1.8%, while operating profit increased 1.6%, ordinary profit declined 0.8% and quarterly net income increased 2.1%.
  14. FY2022Record full-year revenue growth and profit declineAnnual report

    「As a result, full-year revenue increased ¥381 million, or 0.8%, year on year to ¥49,632 million due to higher generic drug sales and other factors. Increases in the cost of sales ratio due to drug price revisions and other factors caused operating profit to decrease ¥427 million, or 18.2%, to ¥1,924 million, ordinary profit to decrease ¥231 million, or 10.4%, to ¥1,996 million, and net income to decrease ¥123 million, or 7.7%, to ¥1,483 million.」

    FY2022 full-year revenue increased 0.8%, while operating profit declined 18.2%, ordinary profit declined 10.4% and net income declined 7.7%.
  15. FY2022-Q3Record modest cumulative nine-month revenue growth and profit declineAnnual report

    「As a result, revenue for the cumulative nine months increased ¥59 million, or 0.2%, year on year to ¥38,271 million. Increases in the cost of sales ratio due to drug price revisions and other factors caused operating profit to decrease ¥437 million, or 18.5%, to ¥1,930 million, ordinary profit to decrease ¥302 million, or 13.1%, to ¥2,006 million, and quarterly net income to decrease ¥175 million, or 10.5%, to ¥1,495 million.」

    In the cumulative nine months, revenue increased 0.2% year on year, while operating profit declined 18.5%, ordinary profit declined 13.1% and quarterly net income declined 10.5%.
  16. FY2022-Q2Record modest first-half revenue growth and profit declineAnnual report

    「As a result, for the cumulative second quarter, revenue was ¥24,966 million, up ¥36 million (0.1%) from the same period of the previous year. On the earnings front, operating profit was ¥1,253 million, down ¥451 million (26.5%) from the same period of the previous year, due mainly to an increase in the cost of sales ratio resulting from drug price revisions and other factors. Ordinary profit was ¥1,353 million, down ¥336 million (19.9%), while quarterly net profit was ¥1,043 million, down ¥249 million (19.3%).」

    In the cumulative second quarter of FY2022, revenue increased 0.1% year on year, while operating profit, ordinary profit and quarterly net income all declined.
  17. FY2022-Q1Record first-quarter revenue growth and profit declineAnnual report

    「As a result, revenue for the cumulative first quarter increased ¥169 million, or 1.4%, year on year to ¥12,599 million due to higher generic drug sales and other factors. However, increases in the cost of sales ratio due to drug price revisions and other factors caused operating profit to decrease ¥355 million, or 36.7%, to ¥612 million, ordinary profit to decrease ¥229 million, or 22.7%, to ¥780 million, and quarterly net income to decrease ¥173 million, or 24.1%, to ¥547 million.」

    In FY2022 first quarter, revenue increased 1.4% year on year due to higher generic drug sales and other factors, while operating profit, ordinary profit and quarterly net income declined due to the higher cost of sales ratio.
  18. FY2021Record full-year revenue and profit growthAnnual report

    「As a result, full-year revenue increased ¥2,349 million, or 5.0%, year on year to ¥49,251 million due to higher generic drug sales and other factors. Higher revenue and an improved cost of sales ratio resulted in operating profit increasing ¥1,340 million, or 132.6%, to ¥2,351 million, ordinary profit increasing ¥1,160 million, or 108.8%, to ¥2,227 million, and net income increasing ¥899 million, or 127.3%, to ¥1,607 million.」

    FY2021 full-year revenue was ¥49,251 million, operating profit was ¥2,351 million, ordinary profit was ¥2,227 million and net income was ¥1,607 million, resulting in revenue and profit growth.
  19. FY2021-Q3Updated: higher revenue and profit for the cumulative third quarterAnnual report

    「As a result, revenue for the cumulative nine months increased ¥1,982 million, or 5.5%, year on year to ¥38,212 million due to higher generic drug sales and other factors. Higher revenue and an improved cost of sales ratio resulted in operating profit increasing ¥1,362 million, or 135.6%, to ¥2,367 million, ordinary profit increasing ¥1,231 million, or 114.2%, to ¥2,309 million, and quarterly net income increasing ¥953 million, or 133.0%, to ¥1,670 million.」

    In the cumulative nine months, revenue increased 5.5%, while operating profit, ordinary profit and quarterly net income also increased year on year due to higher generic drug sales and other factors and an improved cost of sales ratio.
  20. FY2021-Q2Record cumulative second-quarter revenue and profit growthAnnual report

    「As a result, revenue for the cumulative first half increased ¥1,256 million, or 5.3%, year on year to ¥24,930 million due to higher generic drug sales and other factors. Higher revenue and an improved cost of sales ratio resulted in operating profit increasing ¥1,124 million, or 193.8%, to ¥1,705 million, ordinary profit increasing ¥1,061 million, or 169.1%, to ¥1,689 million, and quarterly net income increasing ¥859 million, or 198.3%, to ¥1,293 million.」

    In the cumulative first half, revenue, operating profit, ordinary profit and quarterly net income all increased year on year due to higher generic drug sales and other factors and an improved cost of sales ratio.
  21. FY2021-Q1Record first-quarter revenue and profit growthAnnual report

    「As a result, revenue for the cumulative first quarter increased ¥681 million, or 5.8%, year on year to ¥12,430 million due to higher generic drug sales and other factors. Higher revenue and an improved cost of sales ratio resulted in operating profit increasing ¥486 million, or 101.0%, to ¥967 million, ordinary profit increasing ¥411 million, or 68.8%, to ¥1,009 million, and quarterly net income increasing ¥311 million, or 75.8%, to ¥721 million.」

    First-quarter revenue, operating profit, ordinary profit and quarterly net income all increased year on year due to higher generic drug sales and other factors and an improved cost of sales ratio.
  22. FY2020Record full-year revenue growth and profit declineAnnual report

    「As a result, full-year revenue increased ¥828 million, or 1.8%, year on year to ¥46,902 million due to higher generic drug sales. Despite higher revenue, the increase in the cost of sales ratio caused operating profit to decrease ¥250 million, or 19.9%, to ¥1,010 million, ordinary profit to decrease ¥212 million, or 16.6%, to ¥1,066 million, and net income to decrease ¥187 million, or 21.0%, to ¥707 million.」

    Full-year revenue increased due to higher generic drug sales, while operating profit, ordinary profit and net income all declined year on year due to the higher cost of sales ratio.
  23. FY2020-Q3Record third-quarter revenue growth and profit declineAnnual report

    「As a result, revenue for the cumulative nine months increased ¥607 million, or 1.7%, year on year to ¥36,229 million due to higher sales of generic drugs. Despite higher revenue, the increase in the cost of sales ratio caused operating profit to decrease ¥237 million, or 19.1%, to ¥1,005 million, ordinary profit to decrease ¥189 million, or 15.0%, to ¥1,078 million, and quarterly net income to decrease ¥157 million, or 18.0%, to ¥716 million.」

    In the cumulative nine months, revenue increased 1.7% due to higher generic drug sales, while operating profit, ordinary profit and quarterly net income all declined due to the higher cost of sales ratio.
  24. FY2020-Q2Record first-half revenue growth and profit declineAnnual report

    「As a result, revenue for the cumulative first half increased ¥723 million, or 3.2%, year on year to ¥23,673 million. Despite higher revenue, the increase in the cost of sales ratio caused operating profit to decrease ¥73 million, or 11.3%, to ¥580 million, ordinary profit to decrease ¥67 million, or 9.7%, to ¥627 million, and quarterly net income to decrease ¥59 million, or 12.0%, to ¥433 million.」

    First-half revenue increased 3.2%, while operating profit, ordinary profit and quarterly net income all declined year on year.
  25. FY2020-Q1Record first-quarter revenue and profit growthAnnual report

    「As a result, revenue for the cumulative first quarter increased ¥390 million, or 3.4%, year on year to ¥11,748 million. Operating profit increased ¥223 million, or 86.5%, to ¥481 million, ordinary profit increased ¥234 million, or 64.6%, to ¥598 million, and quarterly net income increased ¥174 million, or 74.1%, to ¥410 million, due to higher revenue and lower selling, general and administrative expenses.」

    First-quarter revenue, operating profit, ordinary profit and quarterly net income all increased year on year.
  26. FY2019Record full-year revenue growth, operating and ordinary profit growth, and net income declineAnnual report

    「Revenue increased ¥173 million, or 0.4%, year on year to ¥46,074 million despite lower sales of certain products, including Sublood BSG, a replacement fluid for filtration-type artificial kidneys. Operating profit increased ¥463 million, or 58.0%, to ¥1,261 million and ordinary profit increased ¥447 million, or 53.7%, to ¥1,279 million, due to lower manufacturing costs, selling, general and administrative expenses and other factors. However, because a gain on the sale of fixed assets comprising owned real estate was recorded as extraordinary income in the previous fiscal year, net income decreased ¥75 million, or 7.7%, to ¥894 million.」

    FY2019 full-year revenue increased 0.4%, while operating profit and ordinary profit increased. Net income decreased 7.7% due to the year-on-year impact of the gain on the sale of real estate.
  27. FY2019-Q3Record cumulative nine-month revenue growth, operating and ordinary profit growth, and net income declineAnnual report

    「As a result, revenue for the cumulative nine months increased ¥167 million, or 0.5%, year on year to ¥35,622 million. Operating profit increased ¥456 million, or 58.2%, to ¥1,242 million and ordinary profit increased ¥458 million, or 56.7%, to ¥1,268 million, due to lower manufacturing costs and other factors. However, because a gain on the sale of fixed assets comprising owned real estate was recorded as extraordinary income in the same period of the previous year, quarterly net income decreased ¥69 million, or 7.4%, to ¥873 million.」

    In the cumulative nine months, revenue increased 0.5% and operating profit and ordinary profit increased, while quarterly net income decreased 7.4% due to the year-on-year impact of the gain on the sale of fixed assets.
  28. FY2019-Q2Record first-half revenue decline and profit growthAnnual report

    「As a result, revenue for the cumulative first half decreased ¥116 million, or 0.5%, year on year to ¥22,950 million. Efforts to reduce manufacturing costs and other expenses resulted in operating profit increasing ¥328 million, or 100.4%, to ¥654 million, ordinary profit increasing ¥291 million, or 72.3%, to ¥695 million, and quarterly net income increasing ¥227 million, or 85.6%, to ¥492 million.」

    In the cumulative second quarter of FY2019, revenue declined 0.5% year on year, while operating profit increased 100.4%, ordinary profit increased 72.3% and quarterly net income increased 85.6%.
  29. FY2019-Q1Record first-quarter revenue decline and profit growthAnnual report

    「As a result, revenue for the cumulative first quarter decreased ¥151 million, or 1.3%, year on year to ¥11,357 million. Operating profit increased ¥112 million, or 77.4%, to ¥258 million, ordinary profit increased ¥85 million, or 30.7%, to ¥363 million, and quarterly net income increased ¥43 million, or 22.7%, to ¥235 million, reflecting higher revenue.」

    In FY2019 first quarter, revenue declined 1.3% year on year, while operating profit increased 77.4%, ordinary profit increased 30.7% and quarterly net income increased 22.7%.
  30. FY2018Record full-year revenue decline, operating and ordinary profit growth, and net income growthAnnual report

    「Revenue decreased ¥881 million, or 1.9%, year on year to ¥45,900 million. Sales of Kindaly dialysis concentrate for artificial kidneys increased, but this was offset by lower sales of certain products, including physiological saline. Efforts to reduce manufacturing costs resulted in operating profit increasing ¥142 million, or 21.7%, to ¥798 million and ordinary profit increasing ¥190 million, or 29.7%, to ¥832 million. Net income increased ¥108 million, or 12.6%, to ¥970 million, partly because a gain of ¥567 million on the sale of fixed assets comprising owned real estate was recorded as extraordinary income.」

    FY2018 full-year revenue declined due to lower sales of certain products, despite higher dialysis concentrate sales. Operating profit, ordinary profit and net income increased year on year due to lower manufacturing costs and the gain on the sale of fixed assets.
  31. FY2018-Q3Record cumulative nine-month revenue decline, operating and ordinary profit growth, and net income declineAnnual report

    「As a result, revenue for the cumulative nine months decreased ¥747 million, or 2.1%, year on year to ¥35,454 million. Sales of Kindaly dialysis concentrate for artificial kidneys increased, but this was offset by lower sales of certain products, including physiological saline. Efforts to reduce manufacturing costs resulted in operating profit increasing ¥37 million, or 5.1%, to ¥785 million and ordinary profit increasing ¥28 million, or 3.6%, to ¥809 million. Although a gain of ¥567 million on the sale of fixed assets comprising owned real estate was recorded as extraordinary income, quarterly net income decreased ¥18 million, or 1.9%, to ¥943 million.」

    In the cumulative nine months, revenue declined 2.1% year on year due to lower sales of certain products, despite higher Kindaly sales. Operating profit and ordinary profit increased, while quarterly net income decreased 1.9%.
  32. FY2018-Q2Record first-half revenue and profit declineAnnual report

    「As a result, revenue for the cumulative first half decreased ¥652 million, or 2.7%, year on year to ¥23,066 million. Sales of Kindaly dialysis concentrate for artificial kidneys increased, but this was more than offset by lower sales of certain products, including physiological saline. Although efforts were made to reduce manufacturing costs, operating profit decreased ¥108 million, or 25.0%, to ¥326 million, ordinary profit decreased ¥111 million, or 21.6%, to ¥403 million, and quarterly net income decreased ¥141 million, or 34.7%, to ¥265 million as revenue declined.」

    In the cumulative second quarter, sales of Kindaly increased, but revenue, operating profit, ordinary profit and quarterly net income declined year on year due to lower sales of physiological saline and other products.
  33. FY2018-Q1Year-on-year revenue and profit declineAnnual report

    「As a result, revenue for the cumulative first quarter increased to ¥11,509 million, a decrease of ¥342 million, or 2.9%, from the same quarter of the previous year. Operating profit decreased ¥130 million, or 47.2%, to ¥145 million, ordinary profit decreased ¥116 million, or 29.5%, to ¥278 million, and quarterly net income decreased ¥95 million, or 33.2%, to ¥192 million.」

    FY2018 first-quarter revenue, operating profit, ordinary profit and quarterly net income all declined year on year.
  34. FY2017Record full-year revenue and profit growthAnnual report

    「As a result, for the fiscal year, revenue increased ¥1,029 million, or 2.2%, year on year to ¥46,782 million, mainly due to higher sales of Kindaly dialysis concentrate for artificial kidneys. Operating profit increased ¥359 million, or 121.2%, to ¥656 million, and ordinary profit increased ¥469 million, or 272.4%, to ¥642 million, reflecting higher revenue. In addition, a gain of ¥477 million on the sale of fixed assets comprising owned real estate was recorded as extraordinary income, resulting in net income of ¥861 million, compared with net income of ¥10 million in the previous fiscal year.」

    FY2017 full-year revenue was ¥46,782 million, operating profit was ¥656 million, ordinary profit was ¥642 million and net income was ¥861 million, resulting in year-on-year revenue and profit growth against a backdrop of higher dialysis concentrate sales.
  35. FY2017-Q3Updated: higher revenue and profit for the cumulative third quarterAnnual report

    「As a result, for the cumulative third quarter, revenue increased by ¥876 million, or 2.5%, year on year to ¥36,202 million, driven by growth in sales of Kindaly dialysis agents. Operating profit increased by ¥185 million, or 33.0%, to ¥747 million and ordinary profit increased by ¥279 million, or 55.9%, to ¥780 million due to higher sales. In addition, a gain on the sale of fixed assets of ¥477 million from the sale of owned real estate was recorded as an extraordinary gain, resulting in quarterly net income of ¥961 million, an increase of ¥651 million, or 209.5%, from the same period of the previous year.」

    For the cumulative third quarter, revenue increased year on year, driven by growth in dialysis-agent sales, while operating profit, ordinary profit and quarterly net income also increased.
  36. FY2017-Q2Updated: higher revenue and profit for the first halfAnnual report

    「As a result, for the cumulative second quarter, revenue increased by ¥468 million, or 2.0%, year on year to ¥23,718 million, driven by growth in sales of Kindaly dialysis agents. On the profit side, operating profit increased by ¥251 million, or 137.4%, to ¥435 million and ordinary profit increased by ¥330 million, or 180.0%, to ¥514 million, due to higher sales and a lower cost-of-sales ratio. Quarterly net income increased by ¥300 million, or 281.7%, to ¥406 million.」

    For the cumulative second quarter, revenue increased year on year, driven by growth in dialysis-agent sales, while operating profit, ordinary profit and quarterly net income also increased.
  37. FY2017-Q1Revenue and profit increased year on yearAnnual report

    「As a result, for the cumulative first quarter, revenue increased by ¥209 million, or 1.8%, year on year to ¥11,851 million, driven by growth in sales of the Kindaly Series of artificial kidney dialysis agents. Operating profit increased by ¥41 million, or 17.9%, to ¥275 million, ordinary profit increased by ¥31 million, or 8.6%, to ¥394 million, and quarterly net income increased by ¥58 million, or 25.3%, to ¥287 million.」

    The first quarter shifted from the previous fiscal year's revenue decline and substantial profit decline to higher revenue, operating profit, ordinary profit and net income, driven by growth in dialysis-agent sales.
  38. FY2016First statedAnnual report

    「Revenue was ¥45,752 million, a decrease of ¥1,289 million, or 2.7%, from the same period of the previous year. On the profit side, operating profit decreased by ¥500 million, or 62.8%, to ¥296 million due mainly to the decline in revenue; ordinary profit decreased by ¥506 million, or 74.6%, to ¥172 million; and net income for the period decreased by ¥330 million, or 97.0%, to ¥10 million. The effective tax rate after the application of tax-effect accounting increased, partly due to the impact of a change in the tax rate for corporate income taxes and other taxes.」

    The results for the year show decreases in revenue, operating profit, ordinary profit and net income for the period.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Fuso Pharmaceutical Industries yet. It last moved in the Earnings of 2026-08-10: "Other".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Revenue Decline and Sharp Profit Drop | Fuso Pharmaceutical Industries,Ltd. (4538) | Komori